Ondine Biomedical Inc (OBI) NPV
- Add to watchlist
- Create an alert
- This stock can be held in a
n/a
n/a
20.40p
£20.97 million
9.25p
n/a
7.25p
n/a
0.50p (5.13%) Previous:
0.50p
n/a
n/a
3,000
Performance
1 week 1W | 5.13% | 1 year 1Y | 43.94% |
---|---|---|---|
1 month 1M | 5.13% | 2 years 2Y | 80.53% |
3 months 3M | 5.71% | 3 years 3Y | n/a |
6 months 6M | 0% | 5 years 5Y | n/a |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
Year ending: | 31/12/2022 | 31/12/2021 |
---|---|---|
Revenue (CADm) | 0.64 | 2.57 |
Profit before tax (CADm) | (19.37) | (50.09) |
Adjusted EPS (¤): | (10.00) | (63.00) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: Canadian dollars
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Ondine Biomedical assessing Steriwave with Yorkshire partners
5 March 2024 13:50
-
Ondine raises $3.6m to help commercialise Steriwave
13 December 2023 14:43
-
Ondine reports strong research findings from Canadian hospitals
23 October 2023 12:15
-
Appointment of Interim Chief Financial Officer
28 March 2024 12:52
-
First commercial adoption of Steriwave by the NHS
25 March 2024 07:00
-
Grant of Share Options
26 January 2024 07:00
Recent trade data is unavailable. We will be replacing it, however in the meantime the information is available on the London Stock Exchange website.
Annual & interim reports
Annual & interim reports are not available for this stock.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.